VRTX
Vertex Pharmaceuticals
Is VRTX Halal?
Life-preserving medicines are generally permissible, but current marketable debt securities fail liquidity screens.
What You Should Know
Vertex's March 31, 2026 filing shows debt/assets of 0.00%, liquidity/assets of 49.00%, receivables plus cash/assets of 28.28% and net interest income/revenue of 3.84%. Medicines for cystic fibrosis and other serious diseases generally preserve life, but product ingredients, gene-editing and clinical or animal research, reproductive applications and patient access require qualitative review.
⚠️ Concerns
- •Liquidity/assets is 49.00%, above the examined FTSE, MSCI and Malaysia limits
- •Clinical and animal research and gene-editing applications require ethics and scholarly review
- •Marketable debt securities are material to the liquidity calculation
- •Business classification remains incomplete even though the principal medicines support health
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-14.
0 / 26,484.4
12,976.2 / 26,484.4
7,489 / 26,484.4
114.8 / 2,986.9
- Financial
- Fails
- Overall
- Fails
Debt/assets is 0.00%, liquidity/assets is 49.00%, receivables plus cash/assets is 28.28% and interest income/revenue is 3.84%; liquidity/assets exceeds the examined FTSE 33.333% limit.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 49.00%, above the examined MSCI 33.33% total-assets limit; debt and receivables plus cash are below their examined limits.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 49.00%, above the examined Malaysia 33% limit; this is a calculation against the named ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; the liquidity failure is independent of the unavailable market-cap denominator.
Business-activity disclosure
Vertex develops medicines for cystic fibrosis and other serious diseases, including gene-editing and clinical programs. Life-preserving medicines are generally permissible, while product ingredients, clinical and animal research, reproductive applications and patient access require continuing qualitative review.
Limitation: The filing does not allocate revenue into a universal prohibited-activity numerator for ingredients, clinical research, reproductive applications, patient access or downstream use.
Purification
Vertex discloses $114.8 million of net interest income but does not prescribe a scholar-approved purification percentage; the disclosed ratio is evidence for the income screen, not a complete purification prescription.
Inputs, assumptions and primary sources
- Amounts are USD millions from Vertex's March 31, 2026 Form 10-Q and rounded to the nearest tenth where disclosed.
- Vertex reports no interest-bearing debt on the balance sheet; operating lease and other liabilities are excluded.
- Cash and cash equivalents are $5,492.9 million and marketable available-for-sale debt securities are $7,483.3 million; equity securities are excluded.
- Accounts receivable, net are $1,996.1 million and first-quarter revenue is $2,986.9 million; net interest income is $114.8 million.
- The filing does not allocate product, patient, clinical or end-use revenue into a universal prohibited-activity numerator.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →